Allergan plc (NYSE:AGN) has been assigned a consensus recommendation of “Hold” from the twenty-one analysts that are presently covering the firm, Marketbeat reports. One investment analyst has rated the stock with a sell recommendation, sixteen have assigned a hold recommendation and three have assigned a buy recommendation to the company. The average 12-month price objective among brokers that have issued ratings on the stock in the last year is $179.47.
Several research analysts have recently issued reports on AGN shares. SunTrust Banks upped their price target on shares of Allergan from $194.00 to $202.00 and gave the stock a “buy” rating in a report on Tuesday, February 11th. Wells Fargo & Co downgraded shares of Allergan from an “overweight” rating to an “equal weight” rating and set a $198.00 price target for the company. in a report on Wednesday, January 22nd. ValuEngine downgraded shares of Allergan from a “hold” rating to a “sell” rating in a report on Wednesday, October 30th. Finally, UBS Group downgraded shares of Allergan from a “buy” rating to a “neutral” rating and upped their price target for the stock from $189.00 to $203.00 in a report on Tuesday, November 19th.
Institutional investors and hedge funds have recently modified their holdings of the business. World Asset Management Inc boosted its position in shares of Allergan by 0.3% during the 4th quarter. World Asset Management Inc now owns 18,170 shares of the company’s stock worth $3,474,000 after purchasing an additional 53 shares in the last quarter. Raymond James Trust N.A. boosted its position in shares of Allergan by 1.3% during the 3rd quarter. Raymond James Trust N.A. now owns 4,466 shares of the company’s stock worth $752,000 after purchasing an additional 59 shares in the last quarter. Pinnacle Financial Partners Inc. boosted its position in shares of Allergan by 0.3% during the 4th quarter. Pinnacle Financial Partners Inc. now owns 20,282 shares of the company’s stock worth $3,877,000 after purchasing an additional 61 shares in the last quarter. Thrivent Financial for Lutherans lifted its position in Allergan by 0.4% in the 4th quarter. Thrivent Financial for Lutherans now owns 14,962 shares of the company’s stock valued at $2,860,000 after acquiring an additional 64 shares in the last quarter. Finally, Wealthspire Advisors L.P. lifted its position in Allergan by 3.9% in the 4th quarter. Wealthspire Advisors L.P. now owns 1,960 shares of the company’s stock valued at $375,000 after acquiring an additional 73 shares in the last quarter. 83.09% of the stock is currently owned by institutional investors and hedge funds.
Allergan (NYSE:AGN) last announced its quarterly earnings data on Monday, February 10th. The company reported $5.22 EPS for the quarter, beating the consensus estimate of $4.57 by $0.65. Allergan had a negative net margin of 32.76% and a positive return on equity of 9.82%. The business had revenue of $4.35 billion during the quarter, compared to the consensus estimate of $4.09 billion. During the same period in the previous year, the business earned $4.29 earnings per share. The company’s revenue was up 6.6% on a year-over-year basis. On average, equities research analysts predict that Allergan will post 17.4 earnings per share for the current year.
The company also recently declared a quarterly dividend, which will be paid on Friday, March 13th. Shareholders of record on Friday, February 14th will be given a dividend of $0.74 per share. The ex-dividend date is Thursday, February 13th. This represents a $2.96 dividend on an annualized basis and a yield of 1.53%. Allergan’s dividend payout ratio (DPR) is currently 16.78%.
Allergan Company Profile
Allergan plc, a pharmaceutical company, develops, manufactures, and commercializes branded pharmaceutical, device, biologic, surgical, and regenerative medicine products worldwide. The company operates in three segments: US Specialized Therapeutics, US General Medicine, and International. It offers a portfolio of products in various therapeutic areas, including medical aesthetics and dermatology, eye care, neuroscience, urology, gastrointestinal, women's health, and anti-infective therapeutic products.
Recommended Story: Cryptocurrencies
Receive News & Ratings for Allergan Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergan and related companies with MarketBeat.com's FREE daily email newsletter.